Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Peter G. Gibson, Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Christine Jenkins, Matthew J. Peters, Guy B. Marks, Melissa Baraket, Heather Powell, Jodie L. Simpson. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019

Member's Comments

No comment yet.

Related content which might interest you: Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007 Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial Source: International Congress 2019 – Airway infection in COPD Year: 2019 Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008 A randomised controlled trial of zafirlukast in acute asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Randomized controlled trial of nebulized budesonide suspension in acute severe exacerbation of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Randomised controlled trial of azithromycin in smokers with asthma Source: Eur Respir J 2013; 42: 1412-1415 Year: 2013 Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020 Year: 2021 Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021 Year: 2022 Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016 Year: 2017 A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021 Double-blind placebo controlled randomized trial of montelukast in acute RSV bronchiolitis Source: Annual Congress 2007 - Bronchiolitis - viruses, treatment and outcome Year: 2007 Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming Source: Eur Respir J 2003; 22: Suppl. 45, 388s Year: 2003 Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care Year: 2012 Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018